VIDEO: Turing Pharmaceuticals CEO Martin Shkreli: 5,000 Percent Price Boost ‘Not Excessive at All’
In case you hadn't heard, last month, Turing Pharmaceuticals CEO and former hedge fund manager Martin Shkreli got hold of the rights to parasite-zapping drug Daraprim, and then he had the bright idea to raise the price from $13.50 to $750 per pill. Now he has a big public relations problem and a self-created health care crisis on his hands.In case you hadn’t heard, last month, Turing Pharmaceuticals chief executive and former hedge fund manager Martin Shkreli got hold of the rights to parasite-zapping drug Daraprim, and then he had the bright idea to raise the price from $13.50 to $750 a pill. Now he has a big public relations problem and self-created health care crisis on his hands. (Heck, he may even have the makings of a rap sheet.)
Shkreli has trotted out a number of tactics in response to the firestorm directed at him since news of the price hike broke. He’s gotten into ill-advised Twitter wars. He’s tried to reframe the astronomical boost in the cost of Daraprim as the product of philanthropy instead of the profit drive.
Watch as Shkreli tries, and fails, to cure the ensuing global epidemic of Daraprim sticker shock in an interview with CBS News:
–Posted by Kasia Anderson
WAIT BEFORE YOU GO...This year, the ground feels uncertain — facts are buried and those in power are working to keep them hidden. Now more than ever, independent journalism must go beneath the surface.
At Truthdig, we don’t just report what's happening — we investigate how and why. We follow the threads others leave behind and uncover the forces shaping our future.
Your tax-deductible donation fuels journalism that asks harder questions and digs where others won’t.
Don’t settle for surface-level coverage.
Unearth what matters. Help dig deeper.
Donate now.
Film
A documentary tells the story of Carl Bean, a disco star who preached the gospel of love and acceptance at the height of the AIDS crisis.
Health & Wellness
A disruption in federal funds has jeopardized HIV testing and outreach in Mississippi, and researchers warn of a resurgence of the epidemic in the South.
Health & Wellness
Aging with HIV comes with an increased risk of health complications later in life. Is the U.S. health care system prepared to treat this growing population?
Opinion
A HIV survivor and former instructor reflects on his experiences.
The 40th president, though he proved to be less extreme than his campaign promises, ignited a wide transformation that resounds to this day.
In 2017, almost 16,000 people died from complications of the virus.
You need to be a supporter to comment.
There are currently no responses to this article.
Be the first to respond.